I have solid evidence for all five. Here's the full comparative breakdown:
5 Solid Psychiatry Session Topics — Head-to-Head Comparison
The 5 Options
| # | Topic | Core Thesis |
|---|
| 1 | Positive Psychotherapy (PPT) | Treat the whole person, not just the illness |
| 2 | Psychedelic-Assisted Therapy | Neuroplasticity, ego dissolution, and the therapeutic trip |
| 3 | Gut-Brain Axis & Psychobiotics | Your microbiome shapes your mood |
| 4 | Neuromodulation (TMS/TIS) | Rewiring the brain with magnets and electricity |
| 5 | Neuroinflammation & Depression | Is depression an inflammatory disease? |
Detailed Comparison
1. 🌱 Positive Psychotherapy (PPT)
Core claim: Depression and mental illness aren't just the presence of suffering — they're also the absence of flourishing. Fixing one doesn't automatically produce the other.
Neuroscience depth: Medium. Dopaminergic reward circuits, vagal tone, BDNF, anterior cingulate cortex activation in positive emotion. Not as mechanistically rich as the other options, but rich enough.
Evidence base:
- 2026 RCT: PPT outperforms CBT at 18-month follow-up for depression (PMID 41827644) — fresh off the press
- 2025 RCT: effective in fibromyalgia (PMID 40912975)
- 2024 meta-analysis: positive psychological interventions improve QoL and mood in cancer patients (PMID 38979929)
- Foundational: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, §32.16 — full dedicated chapter with the 14-session model
Controversy level: Low-medium. It challenges the DSM deficit model, but won't get people angry.
Interactivity: ⭐⭐⭐⭐⭐ — Built-in live exercises (gratitude letter, signature strengths, Three Good Things). You can run one in the room.
Unique strength: Personally relevant to med students drowning in pathology-focused training. Refreshing and applicable to their own wellbeing right now.
Weakness as a session: Less "wow" factor than the others. Lighter on hardcore neuroscience. May feel more like a wellness talk if not framed carefully.
Best for: A group that wants clinical application + self-care + a paradigm challenge to psychiatry's deficit model.
2. 🍄 Psychedelic-Assisted Therapy
Core claim: Controlled use of psilocybin, MDMA, and ketamine — paired with structured psychotherapy — produces rapid, durable remission in treatment-resistant conditions via neuroplasticity windows and default mode network disruption.
Neuroscience depth: ⭐⭐⭐⭐⭐. 5-HT2A agonism → default mode network (DMN) suppression → ego dissolution → increased synaptic plasticity (BDNF, AMPA potentiation) → therapeutic "window" for psychological integration. Can draw this on a whiteboard beautifully.
Evidence base:
- 2024 Cochrane meta-analysis: psychedelics for anxiety/depression in terminal illness (PMID 39260823)
- 2025 Am J Psychiatry review on MDMA-AT (PMID 39741438)
- 2026 review: clinical applications + regulatory landscape (PMID 41944071)
- 2025 review: psychedelics and suicide outcomes (PMID 40094838)
- Bonus hot story: FDA rejection of MDMA-AT for PTSD (2024) — regulatory controversy is built-in content
Controversy level: ⭐⭐⭐⭐⭐. Scheduling, abuse potential, the "mystical experience as mechanism" debate, ethical concerns about who gets to use these.
Interactivity: ⭐⭐⭐⭐⭐. Students will have strong, divided opinions. "Should we legalize therapeutic psilocybin?" is a natural debate format.
Unique strength: The neuroscience is genuinely spectacular — DMN suppression and ego dissolution are concepts that will stick for years. The FDA drama makes it feel urgent and real.
Weakness: Can drift into a vague drug policy discussion if not tightly anchored to mechanism. Needs strong facilitation.
Best for: A neuro-heavy crowd that wants cutting-edge science plus ethical controversy.
3. 🦠 Gut-Brain Axis & Psychobiotics
Core claim: The 100 trillion microorganisms in your gut produce neurotransmitters, modulate the vagus nerve, regulate immune signaling, and directly shape psychiatric outcomes — including depression, anxiety, and possibly psychosis.
Neuroscience depth: ⭐⭐⭐⭐⭐. Enteric nervous system, vagus nerve as bidirectional highway, gut bacteria producing 90% of peripheral serotonin, GABA, SCFA production, HPA axis modulation, intestinal permeability and neuroinflammation. Mechanistically very teachable.
Evidence base:
- 2025 systematic review: gut microbiota variations in depression and anxiety (PMID 40312666)
- 2024 reviews on gut microbiota modulating neurotransmitters and gut-brain signaling (PMID 39106786)
- 2024 comprehensive review: microbiome, metabolomics, hormones, stress and mental health (PMID 39273008)
- Emerging: FMT (fecal microbiota transplant) in psychiatric conditions, psychobiotic trials
Controversy level: ⭐⭐⭐⭐. Is the field overselling probiotics? Correlation vs. causation problems are strong here — great critical thinking exercise.
Interactivity: ⭐⭐⭐⭐. The "poop-mood connection" is inherently memorable. "Design your own psychobiotic trial" is a fun group activity.
Unique strength: Integrates gastroenterology + immunology + neuroscience + psychiatry. Genuinely surprising to most students. Diet and lifestyle feel tangible.
Weakness: Clinical translation is still thin. The "so what can psychiatrists do about it?" answer is currently limited to diet advice and maybe probiotics. Can feel pre-mature.
Best for: Students who want mechanistic depth across systems with an emerging frontier feel.
4. ⚡ Neuromodulation: TMS, TBS & Temporal Interference Stimulation
Core claim: Non-invasive brain stimulation — from rTMS to the brand new temporal interference stimulation (TIS) — is moving from a niche ECT-adjacent tool to a mainstream, precision psychiatry intervention for depression, OCD, PTSD, and addiction.
Neuroscience depth: ⭐⭐⭐⭐⭐. Faraday induction, cortical excitability, long-term potentiation/depression, dorsolateral prefrontal cortex targeting, theta burst protocols (3 min treatment), deep brain stimulation comparison, and TIS as a completely new modality that can stimulate deep brain structures non-invasively.
Evidence base:
- 2025 consensus review on TMS for depression endorsed by three major societies — Am J Psychiatry (PMID 39756350)
- 2025 Am J Psychiatry clinician's guide to rTMS (PMID 40302403)
- 2025 systematic review on temporal interference stimulation — entirely new technique (PMID 41167554)
- FDA-approved: rTMS for MDD, OCD; accelerated TBS now emerging
Controversy level: ⭐⭐⭐. Less socially controversial, but the mechanism debates (is it LTP? Placebo? Circuit normalization?) are intellectually juicy.
Interactivity: ⭐⭐⭐. Less "personal" than the others but great for mechanism diagrams, case studies of treatment-resistant patients.
Unique strength: The most clinically "ready" and mainstream topic. Students will encounter TMS in practice. TIS is genuinely brand new and impressive. Clean, tangible neuro content.
Weakness: Less emotionally engaging than psychedelics or PPT. Can feel technical without good clinical storytelling.
Best for: Neuro-club crowds who want hard science + clinical applicability + something they'll see in residency.
5. 🔥 Neuroinflammation: Is Depression an Infectious Disease of the Brain?
Core claim: A significant subset of depression, psychosis, and bipolar disorder may be driven by chronic low-grade neuroinflammation — opening the door to anti-inflammatory treatments (NSAIDs, minocycline, IL-6 blockers) as psychiatric drugs.
Neuroscience depth: ⭐⭐⭐⭐⭐. Microglia activation, IDO enzyme hijacking tryptophan toward kynurenine (away from serotonin), IL-1β/IL-6/TNF-α in the brain, BBB permeability, the "sick behavior" model, CRP as a psychiatric biomarker, omega-3 modulation of neuroinflammation (
PMID 39513898).
Evidence base:
- Multiple 2024-2025 reviews on neuroinflammatory mechanisms in mood disorders
- Growing RCT literature on anti-inflammatory augmentation (celecoxib, minocycline, infliximab) in depression
- Natural bridge to the gut-brain axis (gut permeability → systemic inflammation → neuroinflammation)
Controversy level: ⭐⭐⭐⭐. Directly challenges the serotonin hypothesis. "Is everything we know about antidepressants based on a flawed model?" is a natural provocative question.
Interactivity: ⭐⭐⭐. Best for case-based discussion ("why does this patient with rheumatoid arthritis on methotrexate report improved mood?").
Unique strength: Unifies psychiatry with the rest of medicine — makes depression feel like a systemic disease. Very relevant after COVID-19 (post-COVID psychiatric syndrome as a neuroinflammatory model).
Weakness: Clinical translation is still emerging. Anti-inflammatory psychiatry is not yet standard of care. Can feel "almost there but not quite."
Best for: Students interested in the biological basis of psychiatry who want to challenge the monoamine hypothesis.
Master Comparison Table
| Criterion | Positive Psychotherapy | Psychedelic Therapy | Gut-Brain Axis | Neuromodulation (TMS) | Neuroinflammation |
|---|
| Neuroscience depth | ⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ |
| Recent evidence | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ |
| Controversy/debate | ⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐⭐ |
| Interactivity | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐⭐ |
| Clinical readiness | ⭐⭐⭐⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐ |
| Personal relevance to students | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐ | ⭐⭐⭐ |
| "Wow, I didn't know that" factor | ⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ |
| Easy to run 2 hrs without running out | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐ |
My Recommendation
If you want a session that's memorable, neuro-rich, and will be talked about after: → Psychedelic-Assisted Therapy. Unmatched neuroscience depth, built-in controversy, live FDA drama.
If you want something more paradigm-shifting for how students think about psychiatry as a field: → Neuroinflammation ("depression is a brain inflammatory disease") or Gut-Brain Axis — both challenge the serotonin model at its roots.
If you want the most interactive, personally engaging session that also has a live workshop component: → Positive Psychotherapy. Students leave with something they can use that evening.
If you want the most "clinically grounded, this will help you in residency" feel: → Neuromodulation (TMS). FDA-approved, expanding indications, brand-new techniques.
Want me to build out a full 2-hour session plan — slides outline, timing, discussion questions, and key papers — for whichever one you pick?